Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Het testen van de toevoeging van AZD6738 (Ceralasertib) aan immunotherapie om de tijd zonder kanker te verlengen voor patiënten met niet-kleincellige longkanker

18 september 2026 bijgewerkt door: National Cancer Institute (NCI)

Een gerandomiseerd fase III-onderzoek naar checkpointblokkade bij longkankerpatiënten in de adjuvante setting op basis van pathologische respons na neoadjuvante therapie (CLEAR)

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

PRIMARY OBJECTIVE:

I. To assess for improvement in disease free survival (DFS) in patients who do not achieve pathologic complete response (pCR) following neoadjuvant therapy and patients who receive adjuvant combination immunotherapy with durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab.

SECONDARY OBJECTIVE:

I. To evaluate any difference in overall survival (OS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab.

EXPLORATORY OBJECTIVES:

I. To evaluate any difference in disease free survival (DFS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab according to PD-L1, stage, prior immune checkpoint inhibitor (ICI) type, and histology.

II. To evaluate any difference in overall survival (OS) with patients who receive durvalumab and AZD6738 (ceralasertib) compared to those who receive monotherapy with durvalumab according to PD-L1, stage, prior ICI type, and histology.

CORRELATIVE OBJECTIVE:

I. To perform correlative analyses on tissue and blood biospecimens collected within this trial.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Starting 4-12 weeks after surgery, patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

ARM B: Starting 4-12 weeks after surgery, patients receive AZD6738 orally (PO) twice daily (BID) on days 1-7 and durvalumab IV over 60 minutes on day 8 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.

After completion of study treatment, patients are followed up every 12 weeks for 2 years then every 24 weeks until year 5 then every 12 months until 10 years from randomization.

Studietype

Ingrijpend

Inschrijving (Geschat)

630

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigde Staten
    • Arkansas
      • Jonesboro, Arkansas, Verenigde Staten, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Beverly Hills, California, Verenigde Staten, 90211
        • Tower Cancer Research Foundation
      • Los Angeles, California, Verenigde Staten, 90048
        • Cedars-Sinai Medical Center
      • Tarzana, California, Verenigde Staten, 91356
        • Cedars-Sinai Cancer - Tarzana
      • Torrance, California, Verenigde Staten, 90505
        • Torrance Memorial Physician Network - Cancer Care
    • Connecticut
      • Hartford, Connecticut, Verenigde Staten, 06102
        • Hartford Hospital
      • Meriden, Connecticut, Verenigde Staten, 06451
        • Midstate Medical Center
      • New Britain, Connecticut, Verenigde Staten, 06050
        • The Hospital of Central Connecticut
    • Delaware
      • Millville, Delaware, Verenigde Staten, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, Verenigde Staten, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Verenigde Staten, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, Verenigde Staten, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20010
        • MedStar Washington Hospital Center
      • Washington D.C., District of Columbia, Verenigde Staten, 20007
        • MedStar Georgetown University Hospital
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Verenigde Staten, 30342
        • Emory Saint Joseph's Hospital
      • Decatur, Georgia, Verenigde Staten, 30033
        • Emory Decatur Hospital
      • Johns Creek, Georgia, Verenigde Staten, 30097
        • Emory Johns Creek Hospital
    • Idaho
      • Boise, Idaho, Verenigde Staten, 83712
        • Saint Luke's Cancer Institute - Boise
      • Coeur d'Alene, Idaho, Verenigde Staten, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Verenigde Staten, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Verenigde Staten, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Verenigde Staten, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Verenigde Staten, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Verenigde Staten, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Verenigde Staten, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
    • Illinois
      • Bloomington, Illinois, Verenigde Staten, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Verenigde Staten, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, Verenigde Staten, 62321
        • Illinois CancerCare-Carthage
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern University
      • DeKalb, Illinois, Verenigde Staten, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, Verenigde Staten, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Verenigde Staten, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Verenigde Staten, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Verenigde Staten, 62401
        • Crossroads Cancer Center
      • Eureka, Illinois, Verenigde Staten, 61530
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, Verenigde Staten, 61401
        • Illinois CancerCare-Galesburg
      • Geneva, Illinois, Verenigde Staten, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Verenigde Staten, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, Verenigde Staten, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Kewanee, Illinois, Verenigde Staten, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Lake Forest, Illinois, Verenigde Staten, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Macomb, Illinois, Verenigde Staten, 61455
        • Illinois CancerCare-Macomb
      • Maywood, Illinois, Verenigde Staten, 60153
        • Loyola University Medical Center
      • O'Fallon, Illinois, Verenigde Staten, 62269
        • Cancer Care Center of O'Fallon
      • O'Fallon, Illinois, Verenigde Staten, 62269
        • HSHS Saint Elizabeth's Hospital
      • Oak Brook, Illinois, Verenigde Staten, 60523
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Verenigde Staten, 60462
        • Northwestern Medicine Orland Park
      • Ottawa, Illinois, Verenigde Staten, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Verenigde Staten, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Verenigde Staten, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Verenigde Staten, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, Verenigde Staten, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Verenigde Staten, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Verenigde Staten, 62702
        • Springfield Clinic
      • Springfield, Illinois, Verenigde Staten, 62781
        • Springfield Memorial Hospital
      • Warrenville, Illinois, Verenigde Staten, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Washington, Illinois, Verenigde Staten, 61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kansas
      • El Dorado, Kansas, Verenigde Staten, 67042
        • Cancer Center of Kansas - El Dorado
      • Lawrence, Kansas, Verenigde Staten, 66044
        • Lawrence Memorial Hospital
      • Newton, Kansas, Verenigde Staten, 67114
        • Cancer Center of Kansas - Newton
      • Olathe, Kansas, Verenigde Staten, 66061
        • The University of Kansas Cancer Center - Olathe
      • Salina, Kansas, Verenigde Staten, 67401
        • Salina Regional Health Center
      • Topeka, Kansas, Verenigde Staten, 66606
        • University of Kansas Health System Saint Francis Campus
      • Wellington, Kansas, Verenigde Staten, 67152
        • Cancer Center of Kansas - Wellington
      • Wichita, Kansas, Verenigde Staten, 67214
        • Ascension Via Christi Hospitals Wichita
      • Wichita, Kansas, Verenigde Staten, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Verenigde Staten, 67214
        • Cancer Center of Kansas - Wichita
      • Winfield, Kansas, Verenigde Staten, 67156
        • Cancer Center of Kansas - Winfield
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Glen Burnie, Maryland, Verenigde Staten, 21061
        • UM Baltimore Washington Medical Center/Tate Cancer Center
    • Massachusetts
      • Beverly, Massachusetts, Verenigde Staten, 01915
        • Beverly Hospital
      • Burlington, Massachusetts, Verenigde Staten, 01805
        • Lahey Clinic
      • Gloucester, Massachusetts, Verenigde Staten, 01930
        • Addison Gilbert Hospital
      • Peabody, Massachusetts, Verenigde Staten, 01960
        • Lahey Clinic Peabody
      • Springfield, Massachusetts, Verenigde Staten, 01199
        • Baystate Medical Center
    • Michigan
      • Battle Creek, Michigan, Verenigde Staten, 49017
        • Bronson Battle Creek
      • Brighton, Michigan, Verenigde Staten, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Canton, Michigan, Verenigde Staten, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Chelsea, Michigan, Verenigde Staten, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Flint, Michigan, Verenigde Staten, 48503
        • Hurley Medical Center
      • Flint, Michigan, Verenigde Staten, 48503
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Verenigde Staten, 48503
        • Genesys Hurley Cancer Institute
      • Flint, Michigan, Verenigde Staten, 48503
        • Cancer Hematology Centers - Flint
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • Bronson Methodist Hospital
      • Lansing, Michigan, Verenigde Staten, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, Verenigde Staten, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Muskegon, Michigan, Verenigde Staten, 49444
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Verenigde Staten, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Verenigde Staten, 49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Pontiac, Michigan, Verenigde Staten, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Reed City, Michigan, Verenigde Staten, 49677
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Verenigde Staten, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Verenigde Staten, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Traverse City, Michigan, Verenigde Staten, 49684
        • Munson Medical Center
      • Wyoming, Michigan, Verenigde Staten, 49519
        • University of Michigan Health - West
      • Ypsilanti, Michigan, Verenigde Staten, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Brainerd, Minnesota, Verenigde Staten, 56401
        • Essentia Health Saint Joseph's Medical Center
      • Coon Rapids, Minnesota, Verenigde Staten, 55433
        • Mercy Hospital
      • Deer River, Minnesota, Verenigde Staten, 56636
        • Essentia Health - Deer River Clinic
      • Duluth, Minnesota, Verenigde Staten, 55805
        • Essentia Health Cancer Center
      • Edina, Minnesota, Verenigde Staten, 55435
        • Fairview Southdale Hospital
      • Hibbing, Minnesota, Verenigde Staten, 55746
        • Essentia Health Hibbing Clinic
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Verenigde Staten, 55417
        • Minneapolis VA Medical Center
      • Saint Louis Park, Minnesota, Verenigde Staten, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Verenigde Staten, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Verenigde Staten, 55102
        • United Hospital
      • Sandstone, Minnesota, Verenigde Staten, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Verenigde Staten, 55792
        • Essentia Health Virginia Clinic
    • Mississippi
      • Columbus, Mississippi, Verenigde Staten, 39705
        • Baptist Memorial Hospital and Cancer Center-Golden Triangle
      • Grenada, Mississippi, Verenigde Staten, 38901
        • Baptist Cancer Center-Grenada
      • New Albany, Mississippi, Verenigde Staten, 38652
        • Baptist Memorial Hospital and Cancer Center-Union County
      • Oxford, Mississippi, Verenigde Staten, 38655
        • Baptist Memorial Hospital and Cancer Center-Oxford
      • Southhaven, Mississippi, Verenigde Staten, 38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Cape Girardeau, Missouri, Verenigde Staten, 63703
        • Saint Francis Medical Center
      • Farmington, Missouri, Verenigde Staten, 63640
        • Parkland Health Center - Farmington
      • Sainte Genevieve, Missouri, Verenigde Staten, 63670
        • Sainte Genevieve County Memorial Hospital
      • St Louis, Missouri, Verenigde Staten, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Verenigde Staten, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, Verenigde Staten, 63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Anaconda, Montana, Verenigde Staten, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Verenigde Staten, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Verenigde Staten, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, Verenigde Staten, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Verenigde Staten, 59405
        • Benefis Sletten Cancer Institute
      • Missoula, Montana, Verenigde Staten, 59804
        • Community Medical Center
    • New Hampshire
      • Concord, New Hampshire, Verenigde Staten, 03301
        • New Hampshire Oncology Hematology PA-Concord
      • Manchester, New Hampshire, Verenigde Staten, 03103
        • Solinsky Center for Cancer Care
    • New Jersey
      • Flemington, New Jersey, Verenigde Staten, 08822
        • Hunterdon Medical Center
    • New York
      • Glens Falls, New York, Verenigde Staten, 12801
        • Glens Falls Hospital
      • The Bronx, New York, Verenigde Staten, 10461
        • Montefiore Medical Center-Einstein Campus
    • North Carolina
      • Pinehurst, North Carolina, Verenigde Staten, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
    • North Dakota
      • Fargo, North Dakota, Verenigde Staten, 58103
        • Essentia Health Cancer Center-South University Clinic
    • Ohio
      • Canton, Ohio, Verenigde Staten, 44710
        • Aultman Health Foundation
      • Columbus, Ohio, Verenigde Staten, 43210
        • Ohio State University Comprehensive Cancer Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Newberg, Oregon, Verenigde Staten, 97132
        • Providence Newberg Medical Center
      • Oregon City, Oregon, Verenigde Staten, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Verenigde Staten, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Verenigde Staten, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Verenigde Staten, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, Verenigde Staten, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Bethlehem, Pennsylvania, Verenigde Staten, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Bryn Mawr, Pennsylvania, Verenigde Staten, 19010
        • Bryn Mawr Hospital
      • East Stroudsburg, Pennsylvania, Verenigde Staten, 18301
        • Pocono Medical Center
      • Erie, Pennsylvania, Verenigde Staten, 16505
        • UPMC Hillman Cancer Center Erie
      • Greensburg, Pennsylvania, Verenigde Staten, 15601
        • UPMC Cancer Centers - Arnold Palmer Pavilion
      • Harrisburg, Pennsylvania, Verenigde Staten, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Hazleton, Pennsylvania, Verenigde Staten, 18201
        • Lehigh Valley Hospital-Hazleton
      • Mechanicsburg, Pennsylvania, Verenigde Staten, 17050
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
      • Media, Pennsylvania, Verenigde Staten, 19063
        • Riddle Memorial Hospital
      • Monroeville, Pennsylvania, Verenigde Staten, 15146
        • UPMC Hillman Cancer Center - Monroeville
      • Paoli, Pennsylvania, Verenigde Staten, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • University of Pennsylvania/Abramson Cancer Center
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • UPMC Hillman Cancer Center
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15243
        • UPMC-Saint Clair Hospital Cancer Center
      • West Reading, Pennsylvania, Verenigde Staten, 19611
        • Reading Hospital
      • Wynnewood, Pennsylvania, Verenigde Staten, 19096
        • Lankenau Medical Center
    • South Carolina
      • Georgetown, South Carolina, Verenigde Staten, 29440
        • Tidelands Georgetown Memorial Hospital
    • Tennessee
      • Collierville, Tennessee, Verenigde Staten, 38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Memphis, Tennessee, Verenigde Staten, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908
        • University of Virginia Cancer Center
      • Fredericksburg, Virginia, Verenigde Staten, 22408
        • Hematology Oncology Associates of Fredericksburg Inc
      • Richmond, Virginia, Verenigde Staten, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Verenigde Staten, 23229
        • Virginia Cancer Institute
      • Richmond, Virginia, Verenigde Staten, 23298
        • VCU Massey Comprehensive Cancer Center
      • South Hill, Virginia, Verenigde Staten, 23970
        • VCU Community Memorial Health Center
    • West Virginia
      • Huntington, West Virginia, Verenigde Staten, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Verenigde Staten, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Verenigde Staten, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Antigo, Wisconsin, Verenigde Staten, 54409
        • Aspirus Cancer Care-Antigo-Volm Cancer Center
      • Appleton, Wisconsin, Verenigde Staten, 54911
        • ThedaCare Regional Cancer Center
      • Ashland, Wisconsin, Verenigde Staten, 54806
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Verenigde Staten, 54843
        • Essentia Health-Hayward Clinic
      • La Crosse, Wisconsin, Verenigde Staten, 54601
        • Gundersen Lutheran Medical Center
      • Medford, Wisconsin, Verenigde Staten, 54451
        • Aspirus Medford Hospital
      • Mukwonago, Wisconsin, Verenigde Staten, 53149
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Verenigde Staten, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Rhinelander, Wisconsin, Verenigde Staten, 54501
        • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
      • Spooner, Wisconsin, Verenigde Staten, 54801
        • Essentia Health-Spooner Clinic
      • Stevens Point, Wisconsin, Verenigde Staten, 54481
        • Aspirus Cancer Care - Stevens Point
      • Superior, Wisconsin, Verenigde Staten, 54880
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Verenigde Staten, 53188
        • UW Cancer Center at ProHealth Care
      • Wausau, Wisconsin, Verenigde Staten, 54401
        • Aspirus Cancer Care-Wausau
      • Wisconsin Rapids, Wisconsin, Verenigde Staten, 54494
        • Aspirus Cancer Care - Wisconsin Rapids

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • STEP 0: Patient must be >= 18 years of age

  • STEP 0: Patient must have stage II to select stage IIIB (N2 but excluding N3) non-small cell lung cancer (NSCLC) of any histology using International Association for the Study of Lung Cancer (IASLC) 8th edition. Stage is assessed at time of initiating pre-operative chemo-immunotherapy

  • STEP 0: Patient must fall into one of the following categories:

    • Planning to undergo, be currently undergoing, or recently completed any standard of care neoadjuvant chemo-immunotherapy with plans to undergo surgical resection
    • Recently completed any standard of care neoadjuvant chemo-immunotherapy AND completed surgical resection and are awaiting pCR status.
    • Recently completed any standard of care neoadjuvant chemo-immunotherapy AND completed surgical resection with confirmed non-path complete response (CR) status.

NOTES:

  • Patient must have completed at least 3 cycles of neoadjuvant chemo-immunotherapy before surgery in order to be eligible for Step 1 randomization.

  • Patients who have completed their surgical resection prior to enrollment in step 0 registration must have their surgery date within a window that will allow initiation of EA5231 treatment (cycle 1 day 1) to commence within 4-12 weeks following surgery

    • STEP 1: EA5231 CLEAR randomization for patients without a pCR post-surgery. Patient's with pCR after surgery will be offered to enroll in the SWOG study S2414 INSIGHT instead
    • STEP 1: Patient must have completed R0 resection after standard of care neoadjuvant chemo-immunotherapy (minimum three cycles completed) for stage II to select stage IIIB (N2 but excluding N3) non-small cell lung cancer (NSCLC) of any histology using IASLC 8th Edition
    • STEP 1: Patient must have non-pathological CR status post-surgery. The pathological CR/non-pathological CR status will be determined by local pathology using IASLC criteria and using the surgical sample tissue
    • STEP 1: Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - ≤ 2 (or Karnofsky ≥ 60%)
    • STEP 1: Patient must not have any known EGFR or ALK genetic alterations. Mutation negative status will be determined per local institutional practices and consistent with National Comprehensive Cancer Network (NCCN) guidelines
    • STEP 1: Patient must have undergone a chest CT after surgery and within 28 days prior to step 1 randomization
    • STEP 1: Patient must have recovered from clinically significant adverse events of their most recent therapy/intervention prior to step 1 randomization
    • STEP 1: Patient must not have experienced a toxicity that led to the permanent discontinuation of prior immunotherapy
    • STEP 1: Patient must not be receiving ongoing steroids at a dose of prednisone 10 mg or higher (or equivalent) at the time of step 1 randomization. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) are allowed
    • STEP 1: Patient must not have received or have a plan to receive post-operative radiation therapy (PORT)
    • STEP 1: Patient must not have a history of treatment-related pneumonitis requiring ongoing steroids or supplemental oxygen use
    • STEP 1: Patient must not have a history of interstitial lung disease (ILD)
    • STEP 1: Patient must not have diagnosis of ataxia telangiectasia
    • STEP 1: Patient must not have history of active primary immunodeficiency
    • STEP 1: Patient must not have history of allogenic organ transplantation
    • STEP 1: Patient must have body weight > 30 kg
    • STEP 1: Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:

  • Has achieved menarche at some point

  • Has not undergone a hysterectomy or bilateral oophorectomy

  • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

    • STEP 1: Patient must not expect to conceive or father children by using highly accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must use at least 1 highly effective method of contraception in addition to a condom and continue to use it throughout their time on protocol treatment. Male patients must use a condom plus spermicide throughout their time on while on protocol treatment. In addition, all patients must continue contraception use for at least 6 months after the last dose of protocol treatment. Patients must also not breastfeed while on protocol treatment and for at least 6 months after the last dose of protocol treatment. Patients must not donate sperm while on protocol treatment and for 6 months after the last dose of protocol treatment
    • STEP 1: Patient must not donate blood while on protocol treatment
    • STEP 1: Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
    • STEP 1: Leukocytes ≥ 3,000/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Hemoglobin ≥ 9.0 g/dL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Absolute neutrophil count (ANC) ≥ 1,500/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Platelets ≥ 100,000/mcL (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Total bilirubin ≤ institutional upper limit of normal (ULN) (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 × institutional ULN (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Creatinine clearance ≥ 50 mL/min (estimated using Cockcroft-Gault method or measured) (these labs must be obtained ≤ 28 days prior to step 1 randomization)
    • STEP 1: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of step 1 randomization are eligible for this trial
    • STEP 1: For patients with known chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • STEP 1: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
    • STEP 1: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
    • STEP 1: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
    • STEP 1: Patient must not have received live attenuated vaccine within 30 days prior to the step 1 randomization, while on protocol treatment and within 30 days after the last dose of durvalumab

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Arm A (Durvalumab)

Starting 4-12 weeks after surgery, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.
Procedure: Biospecimen Collection

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling
Procedure: Computed Tomography

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type
Procedure: Echocardiography Test

Undergo echocardiography

Andere namen:
  • Echocardiografie
  • EG
Biologisch: Durvalumab

Given IV

Andere namen:
  • Imfinzi
  • Immunoglobuline G1, anti-(menselijk eiwit B7-H1) (menselijk monoklonaal MEDI4736 zware keten), disulfide met menselijk monoklonaal MEDI4736 Kappa-keten, dimeer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Experimenteel: Arm B (Durvalumab and AZD6738)

Starting 4-12 weeks after surgery, patients receive AZD6738 PO BID on days 1-7 and durvalumab IV over 60 minutes on day 8 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and blood sample collection throughout the study and may undergo echocardiography as clinically indicated.
Procedure: Biospecimen Collection

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling
Procedure: Computed Tomography

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type
Procedure: Echocardiography Test

Undergo echocardiography

Andere namen:
  • Echocardiografie
  • EG
Biologisch: Durvalumab

Given IV

Andere namen:
  • Imfinzi
  • Immunoglobuline G1, anti-(menselijk eiwit B7-H1) (menselijk monoklonaal MEDI4736 zware keten), disulfide met menselijk monoklonaal MEDI4736 Kappa-keten, dimeer
  • MEDI-4736
  • MEDI4736
  • MEDI 4736
Geneesmiddel: Ceralasertib

Given PO

Andere namen:
  • AZD6738

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Disease free survival (DFS)
Tijdsspanne: From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years

Will estimate DFS distributions using the Kaplan-Meier method and employ Cox proportional hazards models to estimate the treatment hazard ratios. The comparison of DFS will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 2.5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates will be accompanied by the corresponding two-sided 95% confidence intervals.
From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall survival (OS)
Tijdsspanne: From randomization to death from any cause, up to 10 years

Will estimate OS distributions using the Kaplan-Meier method and employ Cox proportional hazards models to estimate the treatment hazard ratios. The comparison of OS will use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 2.5%. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates will be accompanied by the corresponding two-sided 95% confidence intervals.
From randomization to death from any cause, up to 10 years
Incidence of adverse events
Tijdsspanne: Up to 10 years

Toxicity will be assessed by summaries by Common Terminology Criteria for Adverse Event grade.
Up to 10 years

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Correlatieve analyses van biospecimens van weefsel, bloed en ontlasting
Tijdsspanne: Tot 10 jaar
Tot 10 jaar
Estimates of treatment effect by sex
Tijdsspanne: Up to 10 years

Estimates of DFS and the corresponding 95% confidence intervals (CIs) by sex.
Up to 10 years
Estimates of treatment effect by race
Tijdsspanne: Up to 10 years

Estimates of DFS and the corresponding 95% CIs by race.
Up to 10 years
Estimates of treatment effect by ethnicity
Tijdsspanne: Up to 10 years

Estimates of DFS and the corresponding 95% CIs by ethnicity.
Up to 10 years
DFS according to PD-L1 status
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
DFS according to stage
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
DFS according to prior immune checkpoint inhibitor (ICI) type
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
DFS according to histology
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
OS according to PD-L1 status
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
OS according to stage
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
OS according to prior ICI type
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years
OS according to histology
Tijdsspanne: Up to 10 years

Will be compared between treatment arms using the logrank test and Cox modeling.
Up to 10 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

National Cancer Institute (NCI)

Onderzoekers

  • Hoofdonderzoeker: Dwight H Owen, ECOG-ACRIN Cancer Research Group

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

7 augustus 2025

Primaire voltooiing (Geschat)

30 juni 2028

Studie voltooiing (Geschat)

30 juni 2028

Studieregistratiedata

Eerst ingediend

12 december 2024

Eerst ingediend dat voldeed aan de QC-criteria

12 december 2024

Eerst geplaatst (Werkelijk)

13 december 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

21 september 2026

Laatste update ingediend die voldeed aan QC-criteria

18 september 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NCI-2024-10081
  • U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
  • NCI-2024-10081 (Register-ID: CTRP (Clinical Trial Reporting Program))
  • EA5231 (Andere identificatie: CTEP)
  • EA5231 (Andere identificatie: ECOG-ACRIN Cancer Research Group)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren